Millenia Hope Inc receives a grant from the National Institutes of Health (USA) to develop new HIV therapeutics in consortium with the University of Pittsburgh and Rutgers University

    WILMINGTON, DE, and MONTREAL, April 19 /CNW Telbec/ - Millenia Hope Inc.,
(MLHP.PK - Frankfurt: MLF.F) in consortium with the University of Pittsburgh
and Rutgers University has been selected by the National Institutes of Health
(USA) to receive more than $4.6 M over the next five years for a project "HIV
RNase H natural product inhibitors" to develop novel HIV therapeutics directed
at the under-explored HIV target ribonuclease H (RNase H). This research
program is driven by Phytomics, a unique technology of Millenia Hope Inc., for
the production and isolation of plant cell culture-derived natural products to
inhibit HIV RNase H, a viral target that is essential for HIV-1 replication
but for which there are no drugs in current clinical development.
    The NIH award will support the efforts of an outstanding group of
internationally-recognized investigators from three institutions. Dr. Michael
A. Parniak, Professor of Molecular Genetics & Biochemistry at the University
of Pittsburgh and Principal Investigator of this multi-team research effort,
has nearly 20 years experience in HIV research and is regarded as a thought
leader in the discovery of drugs targeting HIV RNase H. Dr. Parniak notes
"This project has an excellent probability of discovering new HIV
therapeutics. The research team we have assembled is world-class, and Millenia
Hope's Phytomics technology provides not only a unique but a readily renewable
resource for the discovery and production of novel HIV drugs."
    Dr. Bahige M. Baroudy, President and CSO, Millenia Hope Inc., has
extensive experience in development of new HIV therapeutics and was among the
first to validate HIV entry as a therapeutic target. Structural biologist
Dr. Eddy Arnold at Rutgers is one of the most highly cited HIV research
scientists. Dr. Ronald Levy at Rutgers has developed unique computational
methods to assist in design of new drug entities. The ultimate goal of the
group is to develop a new class of HIV therapeutics that will be effective
against the increasingly prevalent viral strains that are resistant to current
drug therapies.
    Dr. Baroudy noted, "Millenia Hope is honored that NIH recognizes our
Phytomics technology as a source for novel HIV therapeutics. The NIH support
and the willingness of world-class scientists; Drs. Parniak, Arnold and Levy
to collaborate with us in the development of new drugs for the treatment of
HIV infection is an excellent validation of of our Phytomics technology and
our R&D programs." Dr. Baroudy also stated "Millenia Hope's accomplishments
are a tribute to the sound scientific infrastructure in the Province of
Quebec, Canada. We are also indebted to our shareholders who supported us over
the years, especially in acquiring the patent in 2006 that describes the
compounds that inhibit HIV RNase H. This collaborative research project with
Drs. Parniak, Arnold and Levy will realize our objective of developing a new
therapy for HIV."


    Millenia Hope develops innovative treatments and products that enhance
the quality of life and has put in place programs to fight major infectious
diseases and promote healthier lives. Our team is committed to research and
development to deliver on global medical needs and to bring hope through
healthcare solutions.


    Certain statements made in the release may contain language describing
the plans, goals, strategies, intentions, forecasts, and expectations of
Millenia Hope/Millenia Hope Biopharma that may be referred to as
"forward-looking statements." Several important factors could cause actual
results to differ materially from those in such forward-looking statements and
Millenia Hope could encounter unanticipated obstacles and delays in developing
products, services, and markets.

For further information:

For further information: Mr. Hugo Valente, (514) 365-8888, (514)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890